Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD

Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Keith, Baugh, Bryan, Bejou, Nika, Luo, Donghan, Campbell, Jennifer, Seyedkazemi, Sareh, Anderson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044782/
https://www.ncbi.nlm.nih.gov/pubmed/35466761
http://dx.doi.org/10.1177/23259582221088202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044782/
https://www.ncbi.nlm.nih.gov/pubmed/35466761
http://dx.doi.org/10.1177/23259582221088202

Ejemplares similares